摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methyl-4-methylthioacetophenone | 32467-07-5

中文名称
——
中文别名
——
英文名称
3-methyl-4-methylthioacetophenone
英文别名
1-[3-Methyl-4-(methylsulfanyl)phenyl]ethan-1-one;1-(3-methyl-4-methylsulfanylphenyl)ethanone
3-methyl-4-methylthioacetophenone化学式
CAS
32467-07-5
化学式
C10H12OS
mdl
——
分子量
180.271
InChiKey
UJSIWMXCIHGKDT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    42.4
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-methyl-4-methylthioacetophenoneOxone 、 sodium hydride 作用下, 以 乙醇N,N-二甲基甲酰胺丙酮 为溶剂, 反应 27.0h, 生成 5-[5-(3-methyl-4-methylsulfonylphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1,1-dioxo-2,3-dihydrobenzo[d]isothiazole
    参考文献:
    名称:
    Pal, Manojit; Veeramaneni, Venugopal Rao; Kumar, Sanjeev, Journal of the Indian Chemical Society, 2003, vol. 80, # 12, p. 1095 - 1101
    摘要:
    DOI:
  • 作为产物:
    描述:
    2-甲苄基硫醇乙酰氯 在 aluminium chloride 作用下, 以 氯仿 为溶剂, 以80%的产率得到3-methyl-4-methylthioacetophenone
    参考文献:
    名称:
    1-(4-Alkylthiopheny)-2-substituted amino-alcohols and their salts
    摘要:
    根据发明,新的氨基醇可由以下式表示:其中:R.sub.1代表RS、RSO或RSO.sub.2基团,其中R为直链或支链烷基(C.sub.1 -C.sub.10)、乙酰基团或氢原子;R.sub.2和R.sub.3,可能相同也可能不同,代表卤素原子或烷基(C.sub.1 -C.sub.3)、氨基、烷基氨基(C.sub.1 -C.sub.4)、酰胺基、硝基、羧基、羧酸烷氧基、三氟甲基、烷氧基(C.sub.1 -C.sub.4)或烷硫基(C.sub.1 -C.sub.4)基团;R.sub.4代表氢原子或含有1-4个碳原子的直链或支链烷基基团;R.sub.5和R.sub.6,可能相同也可能不同,代表氢原子、取代或非取代的直链或支链烷基(C.sub.1 -C.sub.16)基团、环烷基(C.sub.5 -C.sub.6)基团、炔基(C.sub.3 -C.sub.4)基团、烯基(C.sub.3 -C.sub.4)基团或哌啶、吗啉、吡啶或吡啶咪唑等异环的基团,R.sub.5和R.sub.6也可以与相邻的氮原子形成取代或非取代的杂环基团;其中R.sub.2和R.sub.3中的一个可以是氢原子,或者同时R为RS中的较低烷基(C.sub.1 -C.sub.3)基团时,R.sub.4和R.sub.5为氢原子,R.sub.6为异丙基或叔丁基基团;或者同时R为RSO.sub.2中的甲基基团时,R.sub.4和R.sub.5为氢原子,R.sub.6为异丙基基团。当R.sub.5和R.sub.6代表烷基时,后者可以被氨基、烷基氨基、羟基、烷氧基、苯氧基、取代苯氧基、苯基、取代苯基基团或哌啶啉或吗啉等异环所取代。
    公开号:
    US03954871A1
点击查看最新优质反应信息

文献信息

  • Triazine derivatives, a process for preparing the derivatives, and
    申请人:Idemitsu Kosan Company Limited
    公开号:US04680054A1
    公开(公告)日:1987-07-14
    A triazine derivative represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are each an alkyl group having 1 to 4 carbon atoms, and X.sup.1 and X.sup.2 are each a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 4 carbon atoms, or an alkylthio group having 1 to 4 carbon atoms. This invention also provides a process for efficiently preparing said triazine derivative and a herbicide containing said triazine derivative as effective component.
    一种由以下通式表示的三嗪衍生物:##STR1## 其中R.sup.1和R.sup.2分别是具有1到4个碳原子的烷基基团,X.sup.1和X.sup.2分别是卤素原子、具有1到4个碳原子的烷基基团、具有1到4个碳原子的烷氧基基团或具有1到4个碳原子的烷基基团。本发明还提供了一种有效制备所述三嗪衍生物的方法和含有所述三嗪衍生物作为有效成分的除草剂
  • PYRAZOLONE DERIVATIVES AS NITROXYL DONORS
    申请人:Cardioxyl Pharmaceuticals, Inc.
    公开号:US20150344437A1
    公开(公告)日:2015-12-03
    The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    所披露的主题提供了吡唑酮衍生物化合物,包含这些化合物的药物组合物,包含这些化合物的工具箱,以及使用这些化合物或药物组合物的方法。具体而言,所披露的主题提供了使用这些化合物或药物组合物治疗心力衰竭的方法。
  • Triazine Derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component
    申请人:IDEMITSU KOSAN COMPANY LIMITED
    公开号:EP0191496A2
    公开(公告)日:1986-08-20
    A triazine derivative represented by the general formula: wherein R1 and R2 are each an alkyl group having 1 to 4 carbon atoms, and X1 and X2 are each a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 4 carbon atoms, or an alkylthio group having 1 to 4 carbon atoms. This invention also provides a process for efficiently preparing said triazine derivative and a herbicide containing said triazine derivative as effective component.
    由通式代表的三嗪衍生物: 其中 R1 和 R2 分别为具有 1 至 4 个碳原子的烷基,X1 和 X2 分别为卤素原子、具有 1 至 4 个碳原子的烷基、具有 1 至 4 个碳原子的烷氧基或具有 1 至 4 个碳原子的烷基。 本发明还提供了一种高效制备所述三嗪衍生物和含有所述三嗪衍生物作为有效成分的除草剂的工艺。
  • Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
    作者:Thomas D. Penning、John J. Talley、Stephen R. Bertenshaw、Jeffery S. Carter、Paul W. Collins、Stephen Docter、Matthew J. Graneto、Len F. Lee、James W. Malecha、Julie M. Miyashiro、Roland S. Rogers、D. J. Rogier、Stella S. Yu、Gary D. Anderson、Earl G. Burton、J. Nita Cogburn、Susan A. Gregory、Carol M. Koboldt、William E. Perkins、Karen Seibert、Amy W. Veenhuizen、Yan Y. Zhang、Peter C. Isakson
    DOI:10.1021/jm960803q
    日期:1997.4.1
    A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of ii (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.
  • Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore
    作者:Sunil K. Singh、V. Saibaba、K. Srinivasa Rao、P. Ganapati Reddy、Pankaj R. Daga、S. Abdul Rajjak、Parimal Misra、Y. Koteswar Rao
    DOI:10.1016/j.ejmech.2005.03.016
    日期:2005.10
    Diverse analogs of 1,5-diarylpyrazoles having 3-hydroxymethyl-4-sulfamoyl (SO2NH2)/methyl sulfonyl (SO2Me)-pheny group at N-1 were synthesized and evaluated for their in vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The SAR study mainly involved the variations at positions C-3, C-5 and N-1 of the pyrazole ring. Several small hydrophobic groups at/around position-4 of C-5 phenyl, viz. 3,4-dimethylphenyl analog 9, 3-methyl-4-methylsulfanylphenyl analog 14 and 2,3-dihydrobenzo[b]thiophenyl analog 17, exhibited impressive COX-2 inhibitory potency. In general, the sulfonamide analogues with a CHF2 at C-3 were found to be more potent than those having a CF3 group. The three dimensional quantitative structure activity relationship comprising comparative molecular field analysis (3D-QSAR-CoMFA) afforded the models with high predictivity which further validated the acceptance of hydroxymethyl (CH2OH) group in the hydrophilic pocket of the COX-2 enzyme. (c) 2005 Elsevier SAS. All rights reserved.
查看更多